Form 8-K - Current report:
SEC Accession No. 0001104659-25-005291
Filing Date
2025-01-22
Accepted
2025-01-22 17:00:22
Documents
15
Period of Report
2025-01-21
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm254066d1_8k.htm   iXBRL 8-K 26101
2 EXHIBIT 99.1 tm254066d1_ex99-1.htm EX-99.1 12025
6 GRAPHIC tm254066d1_ex99-1img001.jpg GRAPHIC 4608
  Complete submission text file 0001104659-25-005291.txt   222161

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA repl-20250121.xsd EX-101.SCH 3018
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE repl-20250121_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE repl-20250121_pre.xml EX-101.PRE 22361
17 EXTRACTED XBRL INSTANCE DOCUMENT tm254066d1_8k_htm.xml XML 3683
Mailing Address 500 UNICORN PARK WOBURN MA 01801
Business Address 500 UNICORN PARK WOBURN MA 01801 (781) 222-9600
Replimune Group, Inc. (Filer) CIK: 0001737953 (see all company filings)

EIN.: 822082553 | State of Incorp.: DE | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-38596 | Film No.: 25546598
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)